Skip to content
Company Analysis

Biogen Inc. BIIB

A comprehensive view of key metrics, scores, and financial health for Biogen Inc.

Overview of Biogen Inc.

BIIB NMS
Healthcare Drug Manufacturers - General Large Cap
Biogen Inc. (BIIB), is a Large Cap company, in the Drug Manufacturers - General industry, last closed at $181.55, about 18.4% overvalued vs fair value, +26.5% 1Y return, ranked 512/1111 in sector.
$181.55
-1.81%
As of March 13, 2026
Previous close • Vol 90d: 33.4%
52-Week Range
Market Cap
$26.64B
Enterprise Value
$30.21B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Biogen Inc..

Top Beats
No strong beats yet

Quick Facts

Website https://www.biogen.com
HQ Cambridge, MA
Employees 7,500
Fiscal year Dec 31

Next Events

Earnings Apr 30 Estimated

Fair Value Snapshot

Bear Base Bull
$135
$148
$162
Current: $181.55 -18% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$9.9B
2.2%%
Gross Profit
$7.5B
1.6%%
R&D Expense
$1.8B
-10.2%%
Operating Income (EBIT)
$1.8B
-15.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
120.9%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$700.0K
0.0% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Biogen Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
58
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
68
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing BIIB's balance between Growth (21.3%), Profitability (34.0%), and Safety (44.7%). Growth 21% Safety 45% Profitability 34%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

30th percentile vs peers
30
Key Signals
Rev Growth YoY 2.2% 39p EPS CAGR 3Y -25.0% 40p EPS Growth YoY -21.4% 28p Revenue CAGR 3Y -0.9% 13p
Strengths
  • Current Ratio in top 20% of peers (2.68, 87th percentile)
  • Cash Flow To Debt Ratio in top 20% of peers (6.52, 97th percentile)
  • Quick Ratio in top 20% of peers (2.03, 87th percentile)
  • Strong liquidity position vs peers
Risks
  • Growth below peer median (percentile: 30)

Profitability

47th percentile vs peers
48
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

62th percentile vs peers
63
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Biogen Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$148.10
- - -
-18.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info